It is well recognized that obesity is a big problem and it can induce large economic burden. Obesity affects about 40% people in the America alone and obesity also is the worldwide problem, with about 400 million obese adults. Moreover, another problem of obesity is the increasing prevalence of overweight children. Though bariatric surgery remains the gold treatment modality in the obesity treatment, endoluminal approaches may have the meaningful role for weight control. Endoscopists should have a role in the management of obesity because endoluminal therapies demonstrate their safety and efficacy over the coming years. Endoluminal therapies can be summarized by above methods: space occupying, malabsorption method, and reduction of gastric volume. In this review, we will introduce various restrictive endoscopic procedures in obesity treatment.
In spite of the low complication rates related to laparoscopic bariatrics, there is an increasing attention in endoluminal and/or transgastric instruments for weight loss procedures.
Interest in endoluminal treatments for the obese has been present for many years. The first breakthrough in endoluminal therapy has been the intragastric balloon (IGB), currently the Orbera balloon, but previously referred to as the Bioenterics intragastric balloon (BIB). The IGB provides a short term supplemental therapy. Nowadays, several companies are developing various balloon devices for obesity treatment. This summary will highlight the various developments on IGB.
Various space-occupying devices are used in the world. Nowadays, they are intended to act as a bridging therapy to bariatric surgery by decreasing the patients’ body mass index (BMI) with the using of a balloon in the gastric space [
The balloon is inserted into the stomach through the oral cavity and esophagus using an endoscopic procedure. During procedure, the patient is under sedation. After balloon insertion, balloon is filled with methylene blue mixed saline water, therefore, it expands into a spherical shape balloon. The balloon can be filled with various amounts of saline (from 400 to 700 cc) to best match the patient’s gastric structure. The intra-gastric balloon should be removed approximately after 6 months.
The BIB™ System is currently being tested (Allergan, Irvine, CA, USA).
Fulfillium (Napa, CA, USA) is developing a balloon having multiple compartments. This system has failure detection systems to enable early detection, therefore, endoscopist can remove a leaking balloon prior to collapse, and avoid passage of it to the duodenum (
Other available balloons are the Reshape Balloon, which can provide similar weight loss as the Orbera. Unlike the Orbera, these balloons are in a fixed position within the stomach and as a result there is 26% incidence of significant ulceration along with a 2% incidence of spontaneous balloon deflation. ReShape Medical (San Clemente, CA, USA) performs to a prospective, non-randomized, multicenter study designed to implant up to 20 CE-marked ReShape™ Balloons in twenty patients with BMI between 30 and 40 [
From the clinical view, the IGB can cause three dominant intolerance symptoms: nausea (vomiting), reflux and abdominal pain, all of which are prophylactically treated before and after balloon placement to avoid “early removal”. At present, intolerance symptoms which can lead to early removal occur in 26% of patients. Using only the large Orbera data, the incidence of ulceration, deflation with migration, and small bowel obstruction are negligible.
BAROnova Therapeutics (Goleta, CA, USA) is making the TransPyloric Shuttle™ (TPS) (
BaroSense (Redwood City, CA, USA) has developed the Trans-oral Endoscopic Restrictive Implant System™ (TERIS) (
EndoSphere (Redwood City, CA, USA) has developed SatiSphere™, an endoscopically placed device increasing the food contact time (
Endoscopic endoluminal treatment of obesity can be a noninvasive, cost-effective, and relatively safer option than bariatric surgery. However, there are many debates according to the long efficacy, economic feasibility and durability of these procedures. Anyway, role of therapeutic endoscopist is very important in the obesity management in aspects of the primary modality for managing complications that occur after bariatric surgery as well as endoscopic endoluminal treatment of obesity. In the near future, role of gastroenterologists will be more important in the management of obesity and its related problems.
This is Bioenterics intragastric balloon (BIB) System. It is saline filled space-occupying balloon endoscopically placed into the stomach.
This system is a gastric balloon with multiple compartments. This system has failure detection systems to enable early detection.
This system is TransPyloric Shuttle (TPS). This system restricts food ingestion with repeatedly blocking of the pylorus.
BaroSense Trans-Oral Endoscopic Restrictive Implant System™ (TERIS).
EndoSphere SatiSphere™, an endoscopically placed device to increase the contact time of food as it traverses the duodenum.